Polaryx Therapeutics, Inc. Common Stock Total Assets
Polaryx Therapeutics, Inc. Common Stock total assets. Based on the latest financial reports, Polaryx Therapeutics, Inc. Common Stock (PLYX) holds total assets worth $11.81 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Polaryx Therapeutics, Inc. Common Stock operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Total Assets of Polaryx Therapeutics, Inc. Common Stock (2023–2025)
Total assets of Polaryx Therapeutics, Inc. Common Stock from 2023 to 2025. This chart illustrates how Polaryx Therapeutics, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. See PLYX stock price for real-time trading data and today's change.
Polaryx Therapeutics, Inc. Common Stock - Asset Composition Analysis
Polaryx Therapeutics, Inc. Common Stock Total Assets Breakdown (December 2025)
Polaryx Therapeutics, Inc. Common Stock total assets breakdown as of December 2025. Polaryx Therapeutics, Inc. Common Stock's total assets of $11.81 Million consist of 95.4% current assets and 4.6% non-current assets. Explore PLYX working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 94.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2023–2025)
This chart illustrates how Polaryx Therapeutics, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Polaryx Therapeutics, Inc. Common Stock's current assets represent 95.4% of total assets in 2025, a decrease from 100.0% in 2023.
- Cash Position: Cash and equivalents constituted 94.9% of total assets in 2025, up from 0.1% in 2023.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2023.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Polaryx Therapeutics, Inc. Common Stock Competitors by Total Assets
Key competitors of Polaryx Therapeutics, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Braveheart Bio, Inc. Common Stock
NASDAQ:BRVE
|
USA | $126.96 Million |
|
PHARVARIS N.V. EO -12
F:9EN
|
Germany | €301.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.98 Billion |
Polaryx Therapeutics, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 13.53 | 11.97 | 17.30 |
| Quick Ratio | 13.53 | 11.97 | 17.30 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $10.94 Million | $3.25 Million | $4.71 Million |
Polaryx Therapeutics, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Polaryx Therapeutics, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.18 |
| Latest Market Cap to Assets Ratio | 17.11 |
| Asset Growth Rate (YoY) | 8.4% |
| Total Assets | $5.42 Million |
| Market Capitalization | $92.71 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Polaryx Therapeutics, Inc. Common Stock's assets at a significant premium (17.11x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Polaryx Therapeutics, Inc. Common Stock's assets grew by 8.4% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Polaryx Therapeutics, Inc. Common Stock (2023–2025)
The table below shows the annual total assets of Polaryx Therapeutics, Inc. Common Stock from 2023 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $5.42 Million | +8.38% |
| 2024-12-31 | $5.00 Million | +116.03% |
| 2023-12-31 | $2.31 Million | -- |
About Polaryx Therapeutics, Inc. Common Stock
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-… Read more